1. CD4+ CD56+ hematodermic/plasmacytoid dendritic cell tumor with response to pralatrexate 
Justin J. Leitenberger, BS, Cindy N. Berthelot, MD, Kristel D. Polder, MD, Barbara Pro, MD, Peter McLaughlin, MD, Dan Jones, MD, PhD, Madeleine Duvic, MD 
Journal of the American Academy of Dermatology 
Volume 58, Issue 3, Pages (March 2008)
DOI: /j.jaad
Copyright © 2008 American Academy of Dermatology, Inc. Terms and Conditions

2. Fig 1
Skin tumors before and after pralatrexate therapy. A, Numerous violaceous brown nodules and tumors of face, neck, and upper aspect of chest after second relapse after CHOP chemotherapy. B, Regression of skin lesions after 55 days of pralatrexate therapy.
Journal of the American Academy of Dermatology  , DOI: ( /j.jaad )
Copyright © 2008 American Academy of Dermatology, Inc. Terms and Conditions

3. Fig 2
Positron emission tomography scans before and after pralatrexate therapy. A, Mildly hypermetabolic skin lesions noted in left lower jaw. B, Metabolic response to therapy in cutaneous and subcutaneous nodules.
Journal of the American Academy of Dermatology  , DOI: ( /j.jaad )
Copyright © 2008 American Academy of Dermatology, Inc. Terms and Conditions

4. Fig 3
Hematodermic/plasmacytoid dendritic cell tumor involving skin. A, Dense dermal infiltrate of tumor cells, with blastoid features and high mitotic rate (arrows on inset). B, Tumor cells diffusely expressed CD43 (shown), and CD4, CD56, and CD123 but no T- or B-cell lineage markers. (A, Hematoxylin-eosin stain; original magnification: ×100, inset: ×600; B, CD43 immunostain using peroxidase-conjugated reagents with diaminobenzidine as chromagenic substrate; original magnification: ×400.)
Journal of the American Academy of Dermatology  , DOI: ( /j.jaad )
Copyright © 2008 American Academy of Dermatology, Inc. Terms and Conditions